je.st
news
UPDATE 1-Samsung biopharma unit mulling NASDAQ listing to raise about $1.34 bln
2015-06-29 07:07:13| Semiconductors - Topix.net
Samsung Bioepis Co Ltd, a biopharmaceutical development unit of Samsung Group, is considering listing on the NASDAQ to raise about 1.5 trillion won to fund product development, a Bioepis spokeswoman said on Monday. Samsung Bioepis is 90 percent owned by Samsung Biologics, which is in turn 46 percent owned by Samsung Electronics Co Ltd , 46 percent by the group's de facto holding company Cheil Industries Inc and about 6 percent owned by builder and general trader Samsung C&T Corp Cheil Industries and Samsung C&T are in the midst of a proposed $8 billion merger that has been opposed by activist U.S. hedge fund Elliott Associates.
Tags: update
listing
unit
raise
Category:Electronics and Electrical